Spago Nanomedical Ab

Spago Nanomedical's Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake

Spago Nanomedical's Abstract on Tumorad(R) Accepted for Presentation at Radiopharma Conference

Spago Nanomedical Continues Recruitment in The Phase I/IIa Tumorad-01 Study Following Positive DMC Recommendation

Spago Nanomedical Strengthens CMC and Supply Capabilities to Support Next Phase of Tumorad Development

Spago Nanomedical Year-End Report January-December, 2025